ESC 365 - First-in-man trial of b3-adrenoreceptor agonist treatment in chronic heart failure - impact on diastolic function

ESC Professional Premium Access

First-in-man trial of b3-adrenoreceptor agonist treatment in chronic heart failure - impact on diastolic function

Session: Chronic heart failure - New treatments and trials

Topic: Pharmacotherapy

Speaker: Doctor H. Bahrami (Herlev, DK)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Doctor Hashmat Sayed Zohori Bahrami

Steno Diabetes Center, Copenhagen, Herlev (Denmark)

0 follower

4 more presentations in this session

The I4RON-HF study, Intravenous Iron Isomaltoside for Inpatients veRsus Outpatient Asians with Heart Failure

Speaker: Doctor T. Lee (Kuala Lumpur, MY)

The effects of combined hyperbaric oxygenation and erythropoietin therapy in treatment of heart failure

Speaker: Professor P. Mitrovic (Belgrade, RS)

Myeloperoxidase as therapeutic target in HFpEF

Speaker: Doctor S. Lejeune (Brussels, BE)

Chronic mitochondrial fusion promotor as a novel pharmacological intervention to alleviate left ventricular dysfunction in rats with chronic myocardial infarction

Speaker: Doctor C. Maneechote (Chiang Mai, TH)

Access the full session

Chronic heart failure - New treatments and trials

Speakers: Doctor H. Bahrami, Doctor T. Lee, Professor P. Mitrovic, Doctor S. Lejeune, Doctor C. Maneechote

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources